Qube Research & Technologies LTD Halozyme Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $93.8 Billion
- Q2 2025
A detailed history of Qube Research & Technologies LTD transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 986,069 shares of HALO stock, worth $63.3 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
986,069Holding current value
$63.3 Million% of portfolio
0.05%Shares
20 transactions
Others Institutions Holding HALO
# of Institutions
597Shares Held
126MCall Options Held
365KPut Options Held
317K-
Black Rock Inc. New York, NY17.6MShares$1.13 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$787 Million0.01% of portfolio
-
State Street Corp Boston, MA5.94MShares$381 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA3.47MShares$223 Million0.03% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.4MShares$218 Million3.92% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.95B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...